Global /Taiwan /Healthcare /Biotechnology /6704

Gwo Xi Stem Cell Applied Technology Co. , Ltd.

6704

• TPEX: 6704 • Delayed

22.05TWD 0%

0.6969 USD

As of 20 June 2026, Gwo Xi Stem Cell Applied Technology Co. , Ltd. has a market cap of $66.91M USD, ranking #28424 globally and #1659 in Taiwan. It ranks #2574 in the Healthcare sector, and #500 in the Biotechnology industry.

Global Rank

28424

Country Rank

1659

Sector Rank

2574

Industry Rank

500

Key Stats

Market Cap

$66.91MUSD

2.12B TWD

Enterprise Value

$72.01MUSD

2.28B TWD

Revenue (TTM)

$5.91MUSD

187.02M TWD

EBITDA (TTM)

-$670.71KUSD

-21.22M TWD

Net Income (TTM)

-$2.55MUSD

-80.52M TWD

EBITDA Margin

-11%

Profit Margin

-43%

PS Ratio

11.3

PB Ratio

3.6

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Biotechnology

CEO

Chuan-Feng Chiu open_in_new

Employees

Founded

2011

Website

gwoxi.com.tw open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	0.5%	-4.1%	-11%	-20%	-18%	0.5%	-50%	-30%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	6704 國璽幹細胞應用技術股份有限公司 --- ISIN: TW0006704000 Shares Out.: Shares Outstanding: 95.949M¹ TV: TradingView: TPEX: 6704 SA: Stock Analysis: TPEX: 6704 YF: Yahoo Finance: 6704.TWO GF: Google Finance: TPEX: 6704 BA: Barron's: 6704 MS: Morningstar: ROCO: 6704	22.05 TWD	TV: TradingView: TPEX: 6704 SA: Stock Analysis: TPEX: 6704 YF: Yahoo Finance: 6704.TWO GF: Google Finance: TPEX: 6704 BA: Barron's: 6704 MS: Morningstar: ROCO: 6704

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Gwo Xi Stem Cell Applied Technology Co. , Ltd.

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. The company was founded in 2011 and is based in Zhubei, Taiwan.

Similar Companies

Industry: Biotechnology (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Caliway Biopharmaceuticals Co., Ltd. TWSE: 6919	$5.46B 172.76B TWD 8K%	-	Taiwan
Pell Bio-Med Technology Co., Ltd. TWSE: 6949	$1.61B 50.93B TWD 2K%	-	Taiwan
Lin BioScience, Inc. TPEX: 6696	$1.08B 34.04B TWD 2K%	-	Taiwan
HanchorBio Inc. TWSE: 7827	$726.25M 22.97B TWD 985%	-	Taiwan
HanchorBio Inc. TPEX: 7827	$600.25M 18.98B TWD 797%	-	Taiwan
Locus Cell Co., Ltd. TPEX: 06891	$571.26M 18.06B TWD 754%	-	Taiwan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 273K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 239K%	19.0	United States
argenx SE EBR: ARGX	$47.43B 41.39B EUR 71K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.23B 68.19T KRW 66K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.27B 60.27B AUD 63K%	29.3	Australia
Lonza Group AG SIX: LONN	$41.88B 33.71B CHF 62K%	37.2	Switzerland

chevron_leftBack